The U.S. Environmental Protection Agency has recently proposed amendments to the Guidrlines for the Health Assessment of Suspect Developmental Toxicants. These amendments expand and clarify points made in the original guidelines, and add new information based on advances in the fierd. For example, the original risk assessment guidance was developed around several basic assumptions that were implicit in the earlier document, but that are clearly stated in the propsed amendments. Also, several consensus workshops were held following the completion of the 1986 guidelines, and the conclusions of these workshops have been incorporated. These inc!ude workshops dealing with the relationship of maternal and developmental toxicity, and with the development of an approach for a weight-of-evidence classification. In addition, a reference dose for developmental toxicity (RfDDT) is proposed, based on short-term exposure, to distinguish it from the RfD for chronic exposure. Other proposed changes include the expansion of the functional developmental toxicity section to reflect the Agency's testing guidelines for developmental neurotoxicity, and the human studies section which now gives more guidance on the use of human data in risk assessment. A number of other minor proposed changes are discussed. The final amended guidelines are currently undergoing Agency review and should be completed within the next year.
NIOSH'4' that addressed critical issues in the guidelines had bet:n held following the development of the final guidelines but before publication, so that the conclusions were not included in the: 1986 guidelines. Since that time, three additional workshops have been held, one on weight of evidence,'"' one on the acceptability and interpretation of dermal developmental toxicity studies,'6' and one on the qualitative and quantitative comparability of human and animal developmental neurotoxicity,'" the results of which will be included in the final revision of the guidelines.
Another factor in the revision of the guidelines was that, as part of the Agency-wide implementation of the 1986 guidelines, a course was developed to teach the developmental toxicity risk assessment process to risk assessors in program and regional offices within the Agency. The course includes a briefing that provides basic information on risk assessment, developmental toxicity, and on the assumpti0n.s that are made in developmental toxicity risk assessment and the basis underlying these assumptions. Case studies based on actual data were developed for use as teaching tools. In addition, participants in the course develop their own case studies around scenarios from their experiences in regulatory or field situations. The development and teaching of these courses has been a learning experience for both the participants and the course facilitators; a number of points of clarification were identified that were useful in better explaining the process in the guidelines themselves.
An Agency Working Group (consisting of the authors) was organized to revise the guidelines. As the Working Group reviewed the 1986 guidelines, several areas were identified in which clarifications could be made, where terminology should be updated and made more consistent with that used in other Agency guidelines, and where more recent information should be included. Several major changes were proposed in the guidelines,") as outlined in Table 1 , as well as a number of other changes. An overview of these changes is given in the Supplementary Information section of the guidelines, and the proposed changes will be discussed briefly here.
OVERVIEW AND RATIONALE FOR THE PROPOSED AMENDMENTS

Assumptions in developmental toxicity risk assessment
A number of basic assumptions are made in the risk assessment process that specifically relate to developmental toxicity. Although these assumptions were made in the development of the 1986 guidelines,") they were not directly stated. These assumptions help to more clearly identify the basis for the Agency's approach to risk assessment described in the proposed guidelines. The assumptions, as st,ated in the proposed amendments to the guidelines,'') are shown in Table 2 , and discussed below.
An agent that produces an adverse developmental effect in experirneni'al animal studies is assumed to pose a An agent that produces an adverse developmental effect in expenmental animal studies is assumed to pose a potential hazard to humans All of the four major manifestations of developmental toxicity (death, structural abnormalities, growth alterations, and functional deficits) are of concern The types of developmental effects seen in animal studies are not necessarily assumed to be the same as those that may be produced in the human The most appropriate or sensitive animal species should be used to estimate human risk In general, a threshold is assumed for the dose-response curve for most developmental toxicants potential hazard to humans following exposure during development. This assumption is based on the comparison of data for known human developmental toxicants. Although this database is limited, in almost all cases, the experimental animal data are predictive of a developmental effect in humans.('-' I ) It is assumed that all of the four major manifestations of developmental toxicity (death, structural abnormalitieci, growth alterations, and functional deficits) are of concern. In the past, there has been a tendency to consider only malformations or malformations and death as manifestations of concern. However, growth alterations and functional deficits are also considered adverse developmental effects. Thus, evidence for any of the four major manifestations is considered indicative of an agent's potential for disrupting development and producing a developmental hazard. For each of these manifestations, there is a vanety of end points which must be evaluated to determine if treatment-related changes provide evidence of an agent's ability to disrupt development. The evaluation of specific end points that require scientific judgment on a case by case basis is discussed in the proposed amendments to the guidelines.@)
The types of developmental effects seen in animal studies are not necessarily assumed to be the same as those that may be produced in the human. This assumption is made because it is impossible to determine which will be thle most appropriate species for predicting the specific types of effects seen in humans. From the data on agents that are known human developmental toxicants, there is usually at least one experimental species that mimics the types of effects seen in humans; however, in other species tested, the types of developmental perturbation often have been different. The fact that every species may not react in the same way is probably due to such factors als species-specific differences in critical periods, metabolism, developmental patterns, or mechanisms of action.
It is assumed that the most appropriate species should be used to estimate human risk. When data are not available to suggest the most appropriate species, the most sensitive species will be used for exrrapolation to humans. In the absence of such data, uses of the most sensitive species is based on data indicating that for the majority of known human developmental toxicants, humans are as sensitive or more so than the most sensitive animal species.'"' ') In general, a threshold is assumed for the dose-response curve for most developmental toxicants. This is based on the known capacity of the developing organism to compensate for or to repair a certain amount of damage at thle cellular, tissue, or organ level. In addition, because of the multipotency of cells at certain stages of development, multiple insults at the molecular or cellular level may be required to produce an effect on the whole organism. There are uncertainties concerning this assumption that are being discussed currently in the literat~re.('~.'~)
Functional developmental toxicity
The proposed amendments in this section (Section III.A.3) reflect the current regulatory status for developmeiital neurotoxicity testing in the Agency. The Office of Toxic Substances (OTS) currently has propose:d developmental neurotoxicity testing guidelines, and has finalized two test rules requiring such testing. In addition, the Science Advisory Panel for the Office of Pesticide Programs (OPP) has approved the development of testing guidelines for developmental neurotoxicity testing. The proposed amendments note these activities and indicate the proposed bases for OPP and OTS requirements for such testing.
Relationship of maternal and developmental toxicity
The 1986 guidelines discuss the relationship of maternal and developmental toxicity and the evaluation of developmental toxicity data in the presence of maternal toxicity (Section III.A.4). In the 1986 guidelines, the statement is made that developmental effects at maternally toxic doses should not be discounted as being secondary to maternal toxicity. In the proposed amendments to the guidelines, a stronger statement is made concerning the finding of developmental toxicity in the presence of maternal toxicity; namely, "when adverse developmental effects are produced only at maternally toxic doses, they are still considered to represent developmental toxicity and should not be discounted as being secondary to maternal toxicity." This statement is a reflection of the conclusions at the U.S. EPA-sponsored workshop on maternal and developmental toxicity.'*'
Human studies
The section on human studies in the 1986 guidelines describes the evaluation of human data for developmental toxic effects and discusses important considerations of study design and evaluation, but does not provide much guidance to the risk assessor on the relative importance of various types of human data. The proposed amendments reorganize and modify this section to give more specific information on interpretation of various types of human studies. They also provide guidance on the use of human data in risk assessment by giving information for weight of evidence. For example, the proposed amendments indicate that "greatest weight should be given to carefully designed epidemiologic studies with more precise measures of exposure; studies with a low probability of biased data should carry more weight in risk assessment."
Weight of evidence for developmental toxicity
The weight-of-evidence scheme for developmental toxicity was developed originally at an EPA-sponsored w~rkshop,'~) with changes made based on comments received in the Agency review of the proposed amendments. The scheme is intended to categorize the database into one of three broad categories to provide an indication of the strength of the database for assessing the potential hazard to humans. The scheme indicates the reviewer's confidence in the database, not the level of concern over a particular agent. The weight-of-evidence category should never be used alone to indicate risk or lack of risk to humans. Instead, the classification should always be presented in conjunction with information on dose-response [ i.e., the effective dose range, no observed adverse effect level (NOAEL), lowest observed adverse effect level (LOAEL), and the RfD,,] and anticipated levels of human exposure. Placing an agent in a particular weight-of-evidence category such as "adequate evidence for human developmental toxicity" does not mean that it will be a developmental toxicant at every dose (because of the general assumption of a threshold) or in every situation (e.g., the hazard may vary significantly depending on route and timing of exposure).
The weight-of-evidence scheme (outlined in Table 3 ) defines three levels of confidence for data used to identify developmental hazards and to assess the risk of human developmental toxicity: definitive evidence, adequate evidence, and inadequate evidence. Within the definitive evidence and adequate evidence categories, there are subcategories for evidence indicating adverse effects and for evidence indicating no adverse effects. In both categories, the evidence required to classify an agent as demonstrating no adverse effects is greater than that required to demonstrate an adverse effect and must include evaluations of a variety of potential manifestations of developmental toxicity. Greater evidence for the no adverse effect category is required because it is much more difficult both biologically and statistically to support a finding of no apparent adverse effect than one of an adverse effect. 
DEVELOPMENTAL TOXICITY RISK ASSESSMENT
Most agents meeting current testing requirements would be expected to fall within the adequate evidence category, either indicating potential human developmental toxicity or no apparent potential human developmental toxicity. Many agents for which little or no information is available would be classified in the inadequate category. Few agents would be expected to fall into the definitive evidence category because the human data necessary to meet the criteria for this category would be difficult to obtain.
The choice of the appropriate category may be difficult because of the complex interrelationship that exists among study design, statistical analysis, and biological significance of the data available for evaluation. Therefore, a great deal of scientific judgement based on experience with developmental toxicity data and with the principles of experimental design and statistical analysis may be required to adequately evaluate the database and to determine the most appropriate category for a particular agent. To allow for this, the language used in the scheme is intentionally broad.
Definitive evidence for:
Human developmental toxicity. This category includes agents for which there is sufficient evidence from epidemiologic studies for the scientific community to judge that a cause and effect relationship exists. Case reports in conjunction with other supporting evidence may also be used.
No apparent human developmental toxicity. Agents in this category have not been associated with developmental toxicity in well-executed epidemiologic studies (e.g., case control and cohort) with adequate power. A variety of potential manifestations of developmental toxicity have been studied. Supporting animal data may or may not be available.
Adequate evidence for:
Potential human developmental toxicity. This category includes agents for which sufficient evidence exists for them to be considered potential human developmental toxicants. The minimum evidence necessary for considering an agent a potential human developmental toxicant would include data from an appropriate, well-executed study in a single experimental animal species that demonstrates developmental toxicity, and/or strong suggestive evidence from adequate clinicaliepidemiologic studies. The strength of the evidence increases as it approaches the definition for definitive human developmental toxicity. Evidence may be enhanced by further data, such as studies in additional species or by other routes of exposure, and replication of the findings. Development of pharmacokinetic or mechanistic information may reduce uncertainties in extrapolation to the human. No apparent potential human developmental toxicity. This category includes agents with data from appropriate well-executed studies in several species (at least two) which evaluated a variety of the potential manifestations of developmental toxicity and showed no developmental effects at doses that were minimally toxic to the adult animal. In addition, there may be human data from adequate studies supportive of no adverse effects.
Inadequate evidence for determining potential human developmental toxicity: This category includes agents for which there is less than the minimum sufficient evidence necessary for assessing human risk. However, data on agents that fall into this category may be used to determine the need for additional testing or information that would then, if adequate, move the agent into the adequate evidence category.
This category includes a variety of types of information such as the lack of any data on the developmental toxicity potential of an agent, data from an appropriate well-executed study in a single species showing no developmental toxicity, data from poorly conducted studies in animals (e.g., small numbers of animals, inappropriate dose selection, other confounding factors) or inadequate data in humans. Additionally, data on structure-activity relationships, short-term test data, pharmacokinetic data, or data on metabolic precursors of the agent of interest could be used to call for further testing, but would be considered insufficient by themselves to assess human risk.
Reference dose for developmental toxicity (RjDDT)
The proposed amendments to the 1986 guidelines incorporate terminology (e.g., NOAEL, LOAEL, RfD) that would make the guidelines more consistent with other Agency guidance. The proposed guidelines discuss the identification of the NOAEL andlor LOAEL, the factors used in establishing the appropriate uncertainty factor, and the calculation of the RfD,, which is introduced to describe the reference dose for developmental toxicity. The RfDD, is based on short-term exposure, usually a single dose or dose/day, to distinguish it from the general RfD, which is usually based on chronic exposure.
Identification of a NOAEL and/or LOAEL is based on the highest dose at which no adverse effect is detected (NOAEL) or the lowest dose at which an adverse effect is detected (LOAEL) from any adequate developmental toxicity study. Adequacy of the data to be used must be judged using the weight-of-evidence approach. NOAELs and applied uncertainty factors may be used to determine the RfD,, which is assumed to be below the threshold for any increase in adverse developmental effects.
The size of the uncertainty factor will vary from agent to agent and will require the exercise of scientific judgment, taking into account a number of factors such as the weight of evidence, interspecies differences, and the slope of the dose-response curve. Uncertainty factors for developmental toxicity generally include a ten-fold factor for interspecies variation and a ten-fold factor for intraspecies variation. In general, an additional uncertainty factor is not applied to account for duration of exposure. Additional factors may be applied due to a variety of uncertainties that exist in the database. For example, the standard study design for a developmental toxicity study calls for a low dose that demonstrates a NOAEL, but there may be circumstances where a risk assessment must be based on the results of a study in which a NOAEL for developmental toxicity was not identified. Rather, the lowest dose administered caused significant effect(s) and was identified as the LOAEL. In circumstances where only a LOAEL is available, questions relative to the sensitivity of end points reported, adequacy of dose levels tested, or confidence in the LOAEL reported may require the use of an additional uncertainty factor of The total uncertainty factor selected is then divided into the NOAEWLOAEL for the most sensitive end point from the most appropriate and/or sensitive mammalian species to determine the RfDDT.
Although the Agency currently uses the NOAEL/uncertainty factor approach to establish an RfD,,, discussions of risk extrapolation procedures have noted that improved mathematical tools are needed for developing estimates of potential human developmental r i~k . (~. '~. '~)
These may include approaches such as those proposed by Gaylor,("' Crump,(18) Rai and Van Ryzin,"') Faustman et al. , (20) and others. The development of biologically based dose-response models in developmental toxicology is limited by a number of factors, including a lack of understanding of the biological mechanisms underlying developmental toxicity, intrdinterspecies differences in the types of developmental events, and the influence of maternal effects on the dose-response curve. However, it is important to explore the use of such models, to identify their advantages over current methods used, as well as their limitations.
Other proposed changes in the risk assessment guidelines
Title. The title of the guidelines was proposed to be changed from "Guidelines for the Health Assessment of Suspect Developmental Toxicants" to "Guidelines for Developmental Toxicity Risk Assessment." This proposed change is to simplify the title and to make it more consistent with the titles of other Agency risk assessment guidelines.
Signs of maternal toxicity. In the section of the Proposed Guidelines on End Points of Maternal Toxicity (Section 1II.A. I), a number of signs of maternal toxicity are identified. The proposed amendments include the addition of support from adverse histopathology findings to the use of alterations in organ weights as a sign of maternal toxicity. This change would indicate more clearly the basis for the use of maternal organ changes as signs of maternal toxicity. Short-term testing in devetopmentat toxicity. The proposed amendments to this section include more recent information on the Chernoff/Kavlock assay, in particular, that from the NIOSH-sponsored work~hop'~' on Evaluation of the Chernoff/Kavlock Test for Developmental Toxicity.
Exposure estimates. The human exposure assessment section in the 1986 guidelines focuses primarily on the special considerations concerning exposure assessment for developmental toxicity. The proposed amendments indicate more clearly that since a single exposure at a critical time in development is sufficient to produce an adverse developmental effect, the human exposure estimate used to calculate the margin of exposure is usually based on a single dose that is not adjusted for duration of exposure, and the number of exposures is not considered important unless there is evidence for a cumulative effect.
Risk characterization. Once an estimate of human exposure is made, this can be compared with the NOAEL or LOAEL from animal studies to determine a margin of exposure (MOE). MOEs are estimated for each exposure scenario specific to each chemical. For example, in the case of exposure to a pesticide, exposures may be by the inhalation, oral, or dermal routes, and may vary considerably for mixeriloaders, applicators, field workers, etc. An MOE may be calculated for each situation with different control options (e.g., use of protective clothing, closed cab application). Factors that determine the acceptability of an MOE are similar to those used in selecting, uncertainty factors. If an MOE is considered unacceptable, then various control options or use restrictions may be: considered.
In the final characterization of risk, several components must be presented to the risk manager to allow an informed decision. The weight of evidence, including strengths, weaknesses, and uncertainties about the data, should be presented, along with the NOAELiLOAEL for maternal and for developmental toxicity as well as the RfD,,. In addition, the human exposure estimates should be presented, if available, along with calculation of the MOE. This information will allow an estimate of the risk for human exposure.
An alternative risk assessment approach for noncancer end points
Since the publication of the proposed amendments for developmental toxicity risk assessment,'" scientists within the Agency have continued to discuss the approach used for risk assessment of noncancer effects, that is, those effects for which a threshold is generally assumed. Although the original NRC document'*') provided an important definition of the risk assessment process, it was written based on cancer risk assessment, and does not discuss approaches for noncancer effects. There are several reasons for considering some modification of the NRC approach. For example, hazard identification and dose-response evaluation of noncancer effects are done concurrently with a focus on identifying the NOAEULOAEL. Also, definition of an agent as a developmental toxicant (or as having other noncancer effects) does not indicate that it will have this effect at every dose (as discussed above under weight of evidence). Thus, the identification of a hazard must always be presented along with the dose information. For this reason, one proposal for an alternate approach is presented in Figure 1 . This reflects the combined hazard identification and dose-response evaluation procedures. The result of this evaluation is the weight-of-evidence statement (including strengths, weaknesses, and uncertainties about the data) and the RfD,, or, if available, a risk estimate from a quantitative modeling approach. This information then is combined with the human exposure estimate to characterize the potential for risk from human exposure. 
SUMMARY
The U.S. EPA has taken the lead in developing guidelines for risk assessment in developmental toxicology, the first guideline to be published for a noncancer (and nonmutagenic) effect. Experience with the 1986 guidelines indicated the need to expand and clarify a number of issues, resulting in the Proposed Amendments to the Guidelines for the Health Assessment of Suspect Developmental Toxicants. The Agency is still reviewing the most appropriate approach to risk assessment for noncancer effects, and this is likely to be an evolving process. The final amended developmental toxicity risk assessment guidelines are currently undergoing Agency review and should be completed within the next year.
